Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris; Inserm UMR_S938, Saint-Antoine Research Center, Sorbonne University, Paris, France.
Am J Gastroenterol. 2023 Jul 1;118(7):1196-1203. doi: 10.14309/ajg.0000000000002128. Epub 2022 Dec 14.
Treatment of primary biliary cholangitis (PBC) can improve the GLOBE score. We aimed to assess the association between changes in the GLOBE score (ΔGLOBE) and liver transplantation (LT)-free survival in patients with PBC who were treated with ursodeoxycholic acid (UDCA).
Among UDCA-treated patients within the Global PBC cohort, the association between ΔGLOBE (ΔGLOBE 0-1 : during the first year of UDCA, ΔGLOBE 1-2 : during the second year) and the risk of LT or death was assessed through Cox regression analyses.
Overall, 3,775 UDCA-treated patients were included; 3,424 (90.7%) were female, the median age was 54.0 (interquartile range [IQR] 45.9-62.4) years, and the median baseline GLOBE score was 0.25 (IQR -0.47 to 0.96). During a median follow-up of 7.2 (IQR 3.7-11.5) years, 730 patients reached the combined end point of LT or death. The median ΔGLOBE 0-1 was -0.27 (IQR -0.56 to 0.02). Cox regression analyses, adjusted for pretreatment GLOBE score and ΔGLOBE 0-12 , showed that ΔGLOBE was associated with LT or death (adjusted hazard ratio 2.28, 95% confidence interval 1.81-2.87, P < 0.001). The interaction between baseline GLOBE score and ΔGLOBE 0-1 was not statistically significant ( P = 0.296). The ΔGLOBE 1-2 was associated with LT or death (adjusted hazard ratio 2.19, 95% confidence interval 1.67-2.86, P < 0.001), independently from the baseline GLOBE score and the change in GLOBE score during the first year of UDCA.
UDCA-induced changes in the GLOBE score were significantly associated with LT-free survival in patients with PBC. While the relative risk reduction of LT or death was stable, the absolute risk reduction was heavily dependent on the baseline prognosis of the patient.
原发性胆汁性胆管炎(PBC)的治疗可以改善 GLOBE 评分。我们旨在评估 PBC 患者在接受熊去氧胆酸(UDCA)治疗后,GLOBE 评分(ΔGLOBE)的变化与肝移植(LT)无生存的相关性。
在全球 PBC 队列中接受 UDCA 治疗的患者中,通过 Cox 回归分析评估 ΔGLOBE(ΔGLOBE 0-1:在 UDCA 的第一年期间,ΔGLOBE 1-2:在第二年期间)与 LT 或死亡风险之间的关系。
总体而言,纳入了 3775 名接受 UDCA 治疗的患者;3424 名(90.7%)为女性,中位年龄为 54.0(四分位距[IQR] 45.9-62.4)岁,基线 GLOBE 评分为 0.25(IQR -0.47 至 0.96)。在中位随访 7.2(IQR 3.7-11.5)年后,730 名患者达到 LT 或死亡的联合终点。ΔGLOBE 0-1 的中位数为-0.27(IQR -0.56 至 0.02)。经预处理 GLOBE 评分和ΔGLOBE 0-12 调整的 Cox 回归分析表明,ΔGLOBE 与 LT 或死亡相关(调整后的危险比 2.28,95%置信区间 1.81-2.87,P <0.001)。基线 GLOBE 评分和ΔGLOBE 0-1 之间的交互作用无统计学意义(P = 0.296)。ΔGLOBE 1-2 与 LT 或死亡相关(调整后的危险比 2.19,95%置信区间 1.67-2.86,P <0.001),与基线 GLOBE 评分和 UDCA 治疗第一年 GLOBE 评分的变化无关。
UDCA 诱导的 GLOBE 评分变化与 PBC 患者的 LT 无生存显著相关。虽然 LT 或死亡的相对风险降低是稳定的,但绝对风险降低在很大程度上取决于患者的基线预后。